Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

• 2020

  Sign in to bookmark this resource.

  Sign in
• M. Pamela Griffin; Yuan Yuan; Therese Takas; Joseph Domachowske; Shabir Madhi; Paolo Manzoni
PMID: 32726528DOI: https://dx.doi.org/10.1056/NEJMx200019

---

Access Resources

• Journal ArticleEN

About

This article describes a study on using a single dose of nirsevimab to prevent respiratory syncytial virus (RSV) in preterm infants. It highlights the potential benefits and effectiveness of this treatment. The article has been cited by other studies focusing on RSV prevention and treatment strategies.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Antiviral Agents; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Respiratory Syncytial Virus, Human; Vulnerable Populations; Antibodies, Monoclonal, Humanized; Infant, Premature

Institutions: AstraZeneca; State University of New York - Upstate Medical University; University of the Witwatersrand; University of Colorado; Le Bonheur Children's Hospital; Città della Salute e della Scienza

---

More like this

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease 2023 · State University of New York - Upstate Medical University, AstraZeneca, Dr. Georgi Stranski University Hospital, Quironsalud Madrid University Hospital, Fukuoka Children's Hospital, Hôpital Femme-Mere-Enfant Efficacy of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants With Congenital Heart Disease and Chronic Lung Disease: A Pooled Analysis of Randomised Controlled Trials 2023 · Children's Hospital Colorado, University of the Witwatersrand, Northwestern University, Dr. Georgi Stranski University Hospital, Quironsalud Madrid University Hospital, State University of New York - Upstate Medical University RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing 2024 · AstraZeneca, State University of New York - Upstate Medical University, Seattle Children's Hospital, Northwestern University

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---